Castration-sensitive Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-sensitive Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC [Phase 3]
Phase 3 trial evaluating intermittent ADT with apalutamide monotherapy in metastatic castration-sensitive prostate cancer (mCSPC) is active …
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. [Phase 3]
Phase 3 trial investigating whether combining Mevrometostat (PF-06821497) with enzalutamide improves outcomes versus enzalutamide alone in A…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial [Phase 2]
DIVINE is a Phase 2 trial evaluating stereotactic body radiation therapy with either immediate or delayed androgen receptor pathway inhibito…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response [Phase 3]
Phase 3 clinical trial exploring switching from docetaxel to androgen receptor pathway inhibitors in metastatic castration-sensitive prostat…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial evaluates PDS01ADC in combination with docetaxel and abiraterone for metastatic castration-sensitive and metastatic cast…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC [Phase 3]
Pfizer is conducting a Phase 3 study of talazoparib in combination with enzalutamide for men with DDR gene-mutated metastatic castration-sen…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents [Phase 3]
Phase 3 trial evaluating Saruparib (AZD5305) versus placebo in men with metastatic castration-sensitive prostate cancer receiving physician'…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating adaptive androgen deprivation in combination with docetaxel for metastatic castration-sensitive prostate…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. [Phase 3]
Phase 3 trial update evaluating whether combining mevrometostat with enzalutamide improves outcomes versus enzalutamide alone in ARPI-naïve …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial [Phase 2]
Phase 2 PRTY Trial evaluating FDG-PET-guided metastasis-directed radiation therapy for metastatic hormone-sensitive prostate cancer; current…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial [Phase 2]
A Phase 2 clinical trial (EQUIP) is evaluating estrogen therapy to improve quality of life for men with newly diagnosed or recurrent metasta…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC [Phase 3]
Phase 3 clinical trial update describing an ongoing study of intermittent androgen deprivation therapy with apalutamide monotherapy in metas…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer [Phase 1]
Phase 1 safety and dose-finding study of PRL-02 Depot in men with advanced prostate cancer is currently recruiting, indicating early clinica…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer-sponsored real-world evidence study on metastatic prostate cancer (metastatic castration-sensitive and metastatic castration-resistan…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) [Phase 3]
Phase 3 study evaluating niraparib plus abiraterone and prednisone versus abiraterone alone in HRR gene-mutated metastatic castration-sensit…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) [Phase 3]
Phase 3 trial evaluating niraparib in combination with abiraterone acetate and prednisone vs abiraterone acetate and prednisone in HRR gene-…
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer-sponsored clinical trial evaluating novel hormonal therapies for metastatic castration-sensitive prostate cancer has completed, with …
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) [Phase 2]
An ongoing Phase 2 clinical trial (A-DREAM) is evaluating whether interrupting hormonal therapy in exceptional responders with metastatic pr…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
A clinical trial update reporting completion of a study evaluating apalutamide and enzalutamide in metastatic castration-sensitive prostate …
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer [Phase 2]
Phase 2 clinical trial update of First Strike and Second Strike therapies for high-risk metastatic castration-sensitive prostate cancer, spo…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer [Phase 3]
Phase 3 trial evaluating shorter-duration androgen receptor pathway inhibitor therapy with apalutamide and enzalutamide for patients with lo…
-
CLINICAL_TRIALS other · 2025-10-24Clinical Trial Update: Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy [Phase 4]
A Phase 4 clinical trial is evaluating changes in PSMA expression in prostate cancer in response to hormonal therapy, including both castrat…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy [Phase 2]
Phase 2 clinical trial evaluating the combination of ipilimumab, degarelix, and radical prostatectomy in men with newly diagnosed metastatic…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This ClinicalTrials.gov update reports the completion of a Phase 1 study evaluating relugolix in men with metastatic castration-sensitive an…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer conducted a study of novel hormonal therapies for metastatic castration-sensitive prostate cancer that has completed, with results po…